Compound (84) exhibited significant efficacy in suppressing the proliferation of ATM-deficient HT144 melanoma cells and displayed a favourable pharmacokinetic profile, positioning it as a promising agent for in vivo validation of the synthetic lethality paradigm between ATM loss and ATR inhibition.322. Here, ATM is linked to melanoma.